Efficacy of Strattera in Children and Adolescents with Attention Deficit Hyperactivity Disorder

Children and adolescents (25 boys, nine girls, aged from six to 17 years) with attention deficit hyperactivity disorder (ADHD) were treated with Strattera at the optimal dose of 1.2 mg/day in out-patient conditions. After use of Strattera for three months, assessment of treatment efficacy demonstrated marked and moderate clinical effects in 78.1% of patients. Psychologists’ assessment indicated that 80% of children showed improvements in the volume and rate of switching of attention and almost 60% showed improvements in measures of the stability of attention. EEG studies showed decreases in the “index of slowing” in 70.2% of patients. Strattera was found to have good safety and tolerance in the treatment of children and adolescents with ADHD.